...
首页> 外文期刊>Biomarker Research >Tissue MicroRNA profiles as diagnostic and prognostic biomarkers in patients with resectable pancreatic ductal adenocarcinoma and periampullary cancers
【24h】

Tissue MicroRNA profiles as diagnostic and prognostic biomarkers in patients with resectable pancreatic ductal adenocarcinoma and periampullary cancers

机译:组织MicroRNA谱作为可切除的胰腺导管腺癌和壶腹周围癌患者的诊断和预后生物标志物

获取原文
           

摘要

BackgroundThe aim of this study was to validate previously described diagnostic and prognostic microRNA expression profiles in tissue samples from patients with pancreatic cancer and other periampullary cancers. MethodsExpression of 46 selected microRNAs was studied in formalin-fixed paraffin-embedded tissue from patients with resected pancreatic ductal adenocarcinoma ( n =?165), ampullary cancer ( n =59), duodenal cancer ( n =?6), distal common bile duct cancer ( n =?21), and gastric cancer ( n =?20); chronic pancreatitis ( n =?39); and normal pancreas ( n =?35). The microRNAs were analyzed by PCR using the Fluidigm platform. ResultsTwenty-two microRNAs were significantly differently expressed in patients with pancreatic cancer when compared to healthy controls and chronic pancreatitis patients; 17 miRNAs were upregulated (miR-21-5p, ?23a-3p, ?31-5p, ?34c-5p, ?93-3p, ?135b-3p, ?155-5p, ?186-5p, ?196b-5p, ?203, ?205-5p, ?210, ?222-3p, ?451, ?492, ?614, and miR-622) and 5 were downregulated (miR-122-5p, ?130b-3p, ?216b, ?217, and miR-375). MicroRNAs were grouped into diagnostic indices of varying complexity. Ten microRNAs associated with prognosis were identified (let-7?g, miR-29a-5p, ?34a-5p, ?125a-3p, ?146a-5p, ?187, ?205-5p, ?212-3p, ?222-5p, and miR-450b-5p). Prognostic indices based on differences in expression of 2 different microRNAs were constructed for pancreatic and ampullary cancer combined and separately (30, 5, and 21 indices). ConclusionThe study confirms that pancreatic cancer tissue has a microRNA expression profile that is different from that of other periampullary cancers, chronic pancreatitis, and normal pancreas. We identified prognostic microRNAs and microRNA indices that were associated with shorter overall survival in patients with radically resected pancreatic cancer.
机译:背景本研究的目的是验证胰腺癌和其他壶腹周围癌患者组织样品中先前描述的诊断和预后microRNA表达谱。方法研究了在切除的胰管腺癌(n = 165),壶腹癌(n = 59),十二指肠癌(n = 6),远端胆总管的患者中,在福尔马林固定的石蜡包埋组织中表达了46种选择的微小RNA。癌症(n = 21)和胃癌(n = 20);慢性胰腺炎(n =?39);和正常胰腺(n =?35)。使用Fluidigm平台通过PCR分析微小RNA。结果与健康对照组和慢性胰腺炎患者相比,胰腺癌患者中的22种microRNA表达差异显着。上调了17个miRNA(miR-21-5p,?23a-3p,?31-5p,?34c-5p,?93-3p,?135b-3p,?155-5p,?186-5p,?196b-5p ,?203,?205-5p,?210,?222-3p,?451,?492,?614和miR-622)和5下调(miR-122-5p,?130b-3p,?216b, 217和miR-375)。 MicroRNA被分为复杂程度各异的诊断指标。鉴定了十个与预后相关的microRNA(let-7?g,miR-29a-5p,?34a-5p,?125a-3p,?146a-5p,?187,?205-5p,?212-3p,?222 -5p和miR-450b-5p)。基于胰腺癌和壶腹癌的两种不同的microRNA表达差异构建了预后指标(分别为30、5和21个指标)。结论该研究证实胰腺癌组织具有与其他壶腹癌,慢性胰腺炎和正常胰腺不同的microRNA表达谱。我们确定了预后的microRNA和microRNA指数,与彻底切除胰腺癌患者的总体生存期较短有关。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号